Thrombosis research · 2007
Clinical significance of anti-protein Z antibodies in patients with lupus anticoagulant.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sailer Thomas, Vormittag Rainer, Koder Silvia, Quehenberger Peter, Kaider Alexandra, Pabinger Ingrid
Аннотация
INTRODUCTION: Protein Z serves as cofactor for the inactivation of factor Xa by the plasma protein Z-dependent protease inhibitor. Deficiency of protein Z was reported to exhibit a clinical manifestation like lupus anticoagulant characterised by thrombosis and fetal loss. As anti-protein Z antibodies may be associated with low protein Z levels, we hypothesised that anti-protein Z antibodies might play a role in lupus anticoagulant (LA).
MATERIALS AND METHODS: Anti-protein Z antibodies were measured by commercially available ELISA in 102 LA-patients (69 with and 33 without thrombosis) and 33 healthy volunteers.
RESULTS: Elevated anti-protein Z IgG and/or IgM, IgG and IgM antibody levels were more prevalent among LA-patients (62%, 35%, 45%) than among controls (50%, 25%, 25%), but the difference was only statistically significant for the IgM subtype (p=0.037). Anti-protein Z IgG (odds ratio [OR] 0.77, 95% confidence interval [CI] 0.33-1.82) and IgM (OR 0.82, CI 0.35-1.88) antibody levels in the highest quartile of controls did not indicate an increased risk for thrombosis among LA-patients. Anti-protein Z IgG (OR 2.0, CI 0.5-7.6) and IgM (OR 1.8, CI 0.5-6.6) antibody levels in the highest quartile of controls were more prevalent in women with pregnancy loss than in those with normal pregnancy, but the difference was not statistically significant.
CONCLUSION: Our data indicate that anti-protein Z antibodies are not associated with thrombosis in LA. However, women with LA and pregnancy loss show a tendency towards elevated anti-protein Z antibody levels.
MATERIALS AND METHODS: Anti-protein Z antibodies were measured by commercially available ELISA in 102 LA-patients (69 with and 33 without thrombosis) and 33 healthy volunteers.
RESULTS: Elevated anti-protein Z IgG and/or IgM, IgG and IgM antibody levels were more prevalent among LA-patients (62%, 35%, 45%) than among controls (50%, 25%, 25%), but the difference was only statistically significant for the IgM subtype (p=0.037). Anti-protein Z IgG (odds ratio [OR] 0.77, 95% confidence interval [CI] 0.33-1.82) and IgM (OR 0.82, CI 0.35-1.88) antibody levels in the highest quartile of controls did not indicate an increased risk for thrombosis among LA-patients. Anti-protein Z IgG (OR 2.0, CI 0.5-7.6) and IgM (OR 1.8, CI 0.5-6.6) antibody levels in the highest quartile of controls were more prevalent in women with pregnancy loss than in those with normal pregnancy, but the difference was not statistically significant.
CONCLUSION: Our data indicate that anti-protein Z antibodies are not associated with thrombosis in LA. However, women with LA and pregnancy loss show a tendency towards elevated anti-protein Z antibody levels.